GET DAILY SIGNALSHarrow (HROW) Analyst Targets Average $63, Suggesting +130% Upside from Recent Levels
Key Takeaways
- The $63 central target is the arithmetic mean of roughly eight verified analyst price targets, rounded from an underlying average near $63.
- At the November 9, 2026 close of $27.47, reaching $63 implies about 130% upside — a very large move even after a post-earnings rally.
- Individual targets range widely, from $45 (Leerink Partners) to $88 (Cantor Fitzgerald), reflecting disagreement about profitability versus growth.
- The strongest support is accelerating branded revenue: third-quarter branded sales rose 62% year over year, led by VEVYE and TRIESENCE.
- The biggest risks are a cut to full-year adjusted EBITDA guidance, persistent net losses, and short interest near 20% of the float.
- For more context, explore Major News, Today's Price Move, Forecast, and Earnings pages for Harrow.
- For AI-driven idea generation across the market, explore Trending AI Robots.
Analyst Consensus and Price Targets
Harrow, Inc. (HROW), a Nashville-based eyecare pharmaceutical company, carries a strongly bullish analyst posture, though the individual stock price targets are unusually spread out. The targets reviewed include $60 from Lake Street, $60 from B. Riley Securities, $63 from BTIG, $62 from Ladenburg Thalmann, $70 from H.C. Wainwright, $88 from Cantor Fitzgerald, and $45 from Leerink Partners, with a roughly $59 target from Craig-Hallum. The arithmetic mean of these values is approximately $63, which is the central target used throughout this article.
That spread — roughly $45 to $88 — is wide and signals genuine disagreement. Bulls anchored to the high end (Cantor Fitzgerald, H.C. Wainwright) emphasize the rapid expansion of the branded ophthalmic franchise. Analysts near the low end reflect caution after a first half in which the company missed profitability expectations and slashed its full-year adjusted EBITDA outlook. Several firms have trimmed targets: B. Riley lowered its target from $65 to $60 and Ladenburg from $66 to $62, while Cantor Fitzgerald reduced its target to $88. Even the lowest target, however, sits well above the current share price. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Harrow closed at $27.47 on November 9, 2026, and rallied roughly 16% in after-hours trading to about $32 after reporting third-quarter results. From the $27.47 close, reaching the $63 central target requires a gain of roughly 130%; even measured from the post-earnings level, the move approaches 100%. By any standard, this is a very large required advance.
The path would depend on sustaining the branded-product acceleration into 2027. Third-quarter revenue reached a record $99.3 million, up 39% year over year, with branded revenue up 62% to $83.5 million — about 84% of the total. VEVYE (cyclosporine for dry eye disease) set a record, and TRIESENCE posted its first $10 million-plus quarter. Management reaffirmed full-year 2026 revenue guidance of $350 million to $365 million. The critical question is whether this top-line momentum translates into durable profitability, given the company is still loss-making on a trailing twelve-month basis.
What Could Support a Move Toward the Target
The most concrete support is the branded portfolio's momentum. VEVYE's revenue growth, TRIESENCE's record quarter, and the October 2026 acquisition of TYRVAYA — the only FDA-approved nasal spray for dry eye disease — give management multiple levers, with TYRVAYA expected to contribute more than $30 million in 2027. The July 2026 launch of BYOOVIZ, a ranibizumab biosimilar, and a planned 2027 launch of OPUVIZ (an aflibercept biosimilar) extend the pipeline. GAAP net income turned positive in the third quarter at $9.8 million, versus a $17.3 million loss in the prior quarter. If branded growth continues and margins improve, the valuation could re-rate materially higher from a price-to-sales ratio around 4.
What Could Prevent the Target From Being Reached
Profitability remains the central obstacle. Full-year 2026 adjusted EBITDA guidance was cut to "greater than $40 million," less than half the original $80 million to $100 million range, reflecting higher spending and first-half shortfalls. The company remains unprofitable on a trailing twelve-month basis, and its compounding segment continues to decline. Short interest near 20% of shares outstanding signals meaningful skepticism, and further EBITDA disappointments, slower-than-expected TYRVAYA adoption, or reimbursement friction could keep the multiple compressed. Insider selling and analyst target cuts through 2026 add to the caution.
Technical Levels and Market Structure
The 52-week range of roughly $25.76 to $54.85 frames the technical picture. The $63 target sits about 15% above the 52-week high, meaning it would require a decisive breakout to new highs. The $25.76 low is the key support level below the market, while the 50-day and 200-day moving averages (near $31 and $38) mark nearer-term resistance zones the stock must reclaim first. Harrow has traded below both averages after a multi-month slide, so the technical structure currently favors caution over momentum. From what I see, monitoring these levels closely helps frame realistic expectations.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms differ in their timing assumptions. Investors should watch fourth-quarter 2026 results and whether management meets its "strongest quarter" guidance, the ramp of TYRVAYA and BYOOVIZ, progress toward the reaffirmed $350 million to $365 million revenue range, and any recovery in adjusted EBITDA toward the $40 million-plus target. Additional analyst revisions — up or down — and changes in the elevated short interest will also shape how credible the $63 objective looks over time.
Using AI Tools to Track Momentum
In my view, incorporating systematic signals can complement fundamental work on names like Harrow. Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. The system helps surface opportunities, track positions, and identify trend changes more efficiently than manual review alone. Signals update with evolving data, making them a useful addition alongside core research when assessing a volatile stock.
Final Assessment
Can Harrow stock reach $63? The arithmetic mean of roughly eight analyst targets sits near that level, but the range is wide — from $45 to $88 — and the required move is very large, roughly 100% to 130% depending on the reference price. The bull case rests on accelerating branded revenue, a record third quarter, and a growing pipeline of dry-eye and biosimilar products. The bear case centers on slashed EBITDA guidance, persistent losses, and heavy short interest. Reaching $63 would require both continued top-line execution and a durable turn toward profitability that re-rates the stock above its 52-week high. That outcome is possible but far from assured, and investors should watch the fourth quarter, TYRVAYA's ramp, and analyst revisions closely before drawing conclusions. I'm watching this closely for signs of sustained progress.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HROW's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for HROW turned positive on October 20, 2026. Looking at past instances where HROW's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HROW's RSI Indicator exited the oversold zone, 34 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 56 cases where HROW's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on HROW as a result. In 64 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +12.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where HROW advanced for three days, in 236 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
HROW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HROW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for HROW entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 62 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. HROW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HROW's P/B Ratio (66.319) is slightly higher than the industry average of (6.379). P/E Ratio (-27.162) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (183.387).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a pharmaceutical company
Industry PharmaceuticalsGeneric
Advertisement